Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA) June 24, 2008
ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity March 10, 2008
ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors December 11, 2007
Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. December 1, 2007
Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia. November 3, 2007
